Leerink Partnrs Has Optimistic Outlook of AVDL Q2 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Equities researchers at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of Avadel Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of $0.00 per share for the quarter, up from their prior estimate of ($0.04). The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2025 earnings at $0.10 EPS, FY2026 earnings at $0.75 EPS, FY2027 earnings at $1.35 EPS and FY2028 earnings at $1.70 EPS.

Several other equities analysts have also issued reports on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Avadel Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $12.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of Avadel Pharmaceuticals in a report on Tuesday, March 4th. UBS Group reduced their target price on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating for the company in a report on Monday, January 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Thursday. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $19.43.

Avadel Pharmaceuticals Price Performance

AVDL stock opened at $9.39 on Monday. The firm has a market cap of $907.35 million, a PE ratio of -11.89 and a beta of 1.40. The business has a 50 day moving average of $8.11 and a 200-day moving average of $9.45. Avadel Pharmaceuticals has a 12-month low of $6.38 and a 12-month high of $17.51.

Avadel Pharmaceuticals (NASDAQ:AVDL) last released its earnings results on Wednesday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The company had revenue of $52.51 million during the quarter, compared to analyst estimates of $50.57 million. Avadel Pharmaceuticals had a negative return on equity of 93.34% and a negative net margin of 52.53%. Avadel Pharmaceuticals’s quarterly revenue was up 93.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.30) earnings per share.

Institutional Investors Weigh In On Avadel Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC lifted its position in shares of Avadel Pharmaceuticals by 5.7% during the fourth quarter. Janus Henderson Group PLC now owns 14,080,219 shares of the company’s stock worth $148,117,000 after acquiring an additional 753,332 shares in the last quarter. Two Seas Capital LP lifted its position in shares of Avadel Pharmaceuticals by 90.6% during the fourth quarter. Two Seas Capital LP now owns 4,296,449 shares of the company’s stock worth $45,156,000 after acquiring an additional 2,042,669 shares in the last quarter. Braidwell LP lifted its position in shares of Avadel Pharmaceuticals by 21.2% during the fourth quarter. Braidwell LP now owns 4,105,726 shares of the company’s stock worth $43,151,000 after acquiring an additional 716,787 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Avadel Pharmaceuticals by 2.3% during the fourth quarter. Vanguard Group Inc. now owns 3,953,247 shares of the company’s stock worth $41,549,000 after acquiring an additional 90,147 shares in the last quarter. Finally, Wealth Effects LLC lifted its position in shares of Avadel Pharmaceuticals by 1.1% during the first quarter. Wealth Effects LLC now owns 2,369,122 shares of the company’s stock worth $18,550,000 after acquiring an additional 24,992 shares in the last quarter. Hedge funds and other institutional investors own 69.19% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.